• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antib Ther . A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics agains

tetano

Editor, Senior Moderator
Antib Ther


. 2024 May 3;7(2):164-176.
doi: 10.1093/abt/tbae009. eCollection 2024 Apr. A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants

Marisa L Yang[SUP] 1 [/SUP], Tom Z Yuan[SUP] 1 [/SUP], Kara Y Chan[SUP] 1 [/SUP], Lin Ding[SUP] 1 [/SUP], Zhen Han[SUP] 1 [/SUP], Hector Franco[SUP] 1 [/SUP], Carson Holliday[SUP] 1 [/SUP], Shruthi Kannan[SUP] 2 [/SUP], Edgar Davidson[SUP] 2 [/SUP], Benjamin J Doranz[SUP] 2 [/SUP], Kartik Chandran[SUP] 3 [/SUP], Emily Happy Miller[SUP] 4 [/SUP], Jessica A Plante[SUP] 5 6 [/SUP], Scott C Weaver[SUP] 5 6 [/SUP], Eunice Cho[SUP] 7 [/SUP], Shweta Kailasan[SUP] 7 [/SUP], Lukas Marsalek[SUP] 8 [/SUP], Hoa Giang[SUP] 1 [/SUP], Yasmina Abdiche[SUP] 9 [/SUP], Aaron K Sato[SUP] 1 [/SUP]



Affiliations
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health. To combat SARS-CoV-2 antigenic escape, we developed a rapid, high-throughput pipeline to discover monospecific VHH antibodies and iteratively develop VHH-Fc-VHH bispecifics capable of neutralizing emerging SARS-CoV-2 variants. By panning VHH single-domain phage libraries against ancestral or beta spike proteins, we discovered high-affinity VHH antibodies with unique target epitopes. Combining two VHHs into a tetravalent bispecific construct conferred broad neutralization activity against multiple variants and was more resistant to antigenic escape than the monospecific antibody alone. Following the rise of the Omicron variant, a VHH in the original bispecific construct was replaced with another VHH discovered against the Omicron BA.1 receptor binding domain; the resulting bispecific exhibited neutralization against both BA.1 and BA.5 sublineage variants. A heavy chain-only tetravalent VHH-Fc-VHH bispecific platform derived from humanized synthetic libraries held a myriad of unique advantages: (i) synthetic preconstructed libraries minimized risk of liabilities and maximized discovery speed, (ii) VHH scaffolds allowed for a modular "plug-and-play" format that could be rapidly iterated upon as variants of concern arose, (iii) natural dimerization of single VHH-Fc-VHH polypeptides allowed for straightforward bispecific production and purification methods, and (iv) multivalent approaches enhanced avidity boosting effects and neutralization potency, and conferred more robust resistance to antigenic escape than monovalent approaches against specific variants. This iterative platform of rapid VHH discovery combined with modular bispecific design holds promise for long-term viral control efforts.

Keywords: SARS-CoV-2; VHH; avidity; multivalent; neutralizing antibody; omicron; synthetic library; tetravalent bispecific.

 
Back
Top Bottom